Imax-S Injection contains Iron Sucrose (20 mg/ml) and is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease (CKD) and other clinical conditions where oral iron therapy is ineffective or contraindicated. This intravenous formulation provides a bioavailable source of iron essential for hemoglobin synthesis and erythropoiesis. Imax-S Injection facilitates rapid replenishment of iron stores, improving hemoglobin levels and reducing the need for blood transfusions. The dosage and administration should be individualized based on the patient’s iron requirements, hemoglobin concentration, and response to therapy. It is typically administered by slow intravenous injection or infusion under strict medical supervision to monitor for hypersensitivity reactions. Common adverse effects may include transient hypotension, nausea, injection site reactions, and dizziness. Caution is advised in patients with known hypersensitivity to iron sucrose or other parenteral iron products. Monitoring of serum ferritin and transferrin saturation is recommended to avoid iron overload. Imax-S Injection should be used with caution in patients with active infections, as iron may exacerbate bacterial growth. Proper patient selection and adherence to recommended dosing protocols are essential to maximize therapeutic benefits and minimize risks associated with intravenous iron therapy.